



*[Handwritten signature]*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicant(s)** : Christopher L. Reading, et al.  
**Serial No.** : 10/728,400  
**Filed** : December 5, 2003  
**Title** : Therapeutic Treatment Methods 2  
**TC/A.U.** : 1614  
**Examiner** : Brian S. Kwon

**Docket No.** : 202.14  
**Customer No.** : 26,551  
**Confirmation No.:** 9232

---

**MAIL STOP AMENDMENT**  
**COMMISSIONER FOR PATENTS**  
**P.O. BOX 1450**  
**ALEXANDRIA, VA 22313-1450**

**TRANSMITTAL LETTER**

Dear Sir:

Enclosed are the following papers for filing in this application:

- (X) Supplemental information disclosure statement listing 62 references, which is filed under 37 C.F.R. § 1.97(b)(3).
- (X) First class mailing certificate under 37 C.F.R. § 1.8.
- (X) Return postage prepaid postcard.
- (X) The Commissioner is hereby authorized to charge any fees which may be required, now or in the future, or credit any overpayment to **Deposit Account No. 501536**.
- (X) Please use **Customer No. 26,551** for the correspondence address.

Date: May 20, 2006

*[Handwritten signature: Daryl D. Muenchau]*

Daryl D. Muenchau  
Registration No. 36,616  
Attorney of Record  
Hollis-Eden Pharmaceuticals, Inc.  
4435 Eastgate Mall, Suite 400  
San Diego, CA 92121  
Phone: 858-587-9333



Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


**CERTIFICATE OF MAILING BY FIRST-CLASS MAIL**


Serial No. : 10/728,400  
Docket No. : 202.14  
Applicants : Christopher L. Reading, et al.  
Filed : December 5, 2003  
For : Therapeutic Treatment Methods 2  
Attorney : Daryl D. Muenchau, Registration No. 36,616  
Date of Deposit : May 20, 2006

I hereby certify that the accompanying:

Transmittal letter; Supplemental information disclosure statement; and  
Return postage prepaid postcard

are being deposited with the United States Postal Service First-Class Mail Post Office  
to Addressee service under 37 CFR § 1.8 on May 20, 2006 and are addressed to the  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Daryl Muenchau

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
202.14APPLICATION NO.  
10/728,400SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Reading, et al.FILING DATE  
December 5, 2003GROUP  
1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	2,108,646	2-15-38	Bockmühl et al.			
	2,170,124	8-22-39	Butenandt et al.			
	2,267,257	12-23-41	Ruzcika			
	2,286,892	6-16-42	Bockmühl et al.			
	2,531,441	11-28-50	Julian et al.			
	2,561,378	7-24-51	Julian et al.			
	2,566,336	9-04-51	Julian et al.			
	2,582,258	1-15-52	Julian et al.			
	2,697,107	12-14-51	Ruschig et al.			
	2,705,238	3-29-55	Julian et al.			
	2,843,609	7-17-58	Colton			
	2,845,381	7-29-58	Tindall			
	2,878,267	3-17-59	Szpilfogel et al.			
	2,880,212	3-31-59	Grob et al.			
	2,894,958	7-14-59	Goldberg et al.			
	2,908,696	10-13-59	Nussbaum et al.			
	2,911,418	11-03-59	Johns et al.			
	2,927,119	3-01-60	Ellis et al.			
	3,001,988	9-26-61	Nysted			
	3,004,968	10-17-61	Jeger et al.			
	3,018,298	1-23-62	Klimstra et al.			
	3,060,203	10-23-62	Huffman			
	3,084,156	4-02-63	Counsell et al.			
	3,101,358	4-20-63	De Ruggieri et al.			
	3,107,254	10-15-63	Lednicer			

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>SUPPLEMENTAL INFORMATION DISCLOSURE          STATEMENT BY APPLICANT</b>  (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. <b>202.14</b>	APPLICATION NO. <b>10/728,400</b>
	APPLICANT <b>Reading, et al.</b>	
	FILING DATE <b>December 5, 2003</b>	GROUP <b>1614</b>

### U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	3,124,571	3-10-64	Ringold et al.			
	3,148,198	9-08-64	Goldcamp et al.			
	3,189,597	6-15-65	Belding et al.			
	3,189,623	6-15-65	Ayer			
	3,264,329	8-02-66	Clark et al.			
	3,281,431	10-25-66	Sollman			
	3,282,969	11-01-66	Boswell			
	3,301,872	1-31-67	Sollman			
	3,324,001	6-06-67	Bertin et al.			
	3,325,535	6-13-67	Holden et al			
	3,345,385	10-03-67	Nagata			
	3,357,888	12-12-67	Campbell et al.			
	3,380,886	4-30-68	Campbell et al.			
	3,427,300	2-11-69	Sarett et al.			
	3,436,390	4-01-69	Lefebvre et al.			
	3,673,173	6-27-72	Komeno et al.			
	3,691,207	09-12-72	Klimstra			
	3,738,983	6-12-73	Dryden et al.			
	3,780,073	12-18-73	Shroff			
	3,787,453	1-22-74	Fahrenholtz			
	3,816,480	6-11-74	Lenz			
	3,872,076	3-18-78	Rosen			
	3,917,831	11-4-75	Grunwell et al.			
	3,943,124	3-9-76	Phillipps et al.			
	3,944,576	3-16-76	van den Broek et al.			
	3,987,055	10-19-76	Berlin et al.			
	4,908,358	3-13-90	Schrieber			

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>SUPPLEMENTAL INFORMATION DISCLOSURE          STATEMENT BY APPLICANT</b>  (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. <b>202.14</b>	APPLICATION NO. <b>10/728,400</b>
	APPLICANT <b>Reading, et al.</b>	
	FILING DATE <b>December 5, 2003</b>	GROUP <b>1614</b>

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES)
	Antin, J., et al., Cytokine dysregulation and acute graft-versus-host disease, <i>Blood</i> , 80(12):2964-2968 1992
	Arsenou, E.S., et al., Optimization of the allylic oxidation in the synthesis of 7-keto- $\Delta^5$ -steroidal substrates, <i>Steroids</i> , 68:407-414 2003
	Counsell, R.E., et al., Hypocholesterolemic Agents. III. N-Methyl-N-(dialkylamino)alkyl-17 $\beta$ -aminoandrost-5-en-3 $\beta$ -ol derivatives, <i>J. Med. Pharm. Chem.</i> , 5:1224-1233 1962
	Greinix, H., et al., Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study, <i>Blood</i> , 96(7):2426-2431 2000
	Hervé, P., et al., Phase I-II trial of a monoclonal anti-tumor necrosis factor $\alpha$ antibody for the treatment of refractory severe acute graft-versus-host disease, <i>Blood</i> , 79(12):3362-3368 1992
	Lu, M.C., et al., Inhibition of cholesterol side-chain cleavage. 4. Synthesis of A or B ring modified azacholesterols, <i>J. Med. Chem.</i> , 24:1038-1042 1981
	Martin, P.J., et al., A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment, <i>Blood</i> , 77(8):1821-1828 1991
	Ratanatharathorn, V., et al., Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease, <i>Ann Int Med</i> , 133(4):275-279 2000
	Vogelsang, G.B., How I treat chronic graft-versus-host disease, <i>Blood</i> , 97(5):1196-1201 2001
	Weisdorf, D., et al., Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome, <i>Blood</i> , 75(4):1024-1030 1990

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	